Niina Veitonmäki - Zermatt Consulting

Niina Veitonmäki

Joyful holidays!

Joyful holidays!

Science moves forward through collaboration, curiosity, and commitment. We are grateful for the colleagues, partners, and collaborators who contributed to our work this year and helped advance shared goals. Wishing everyone a well-earned pause and a strong start to the year ahead.

Finally published PBA-0405 data!

Frontiers | A novel fully human anti-ROR1 antibody PBA-0405 optimized for ADCC, induces potent anti-tumor activity against both solid and hematological malignanciesIntroductionB-cell malignancies, including chronic lymphocytic leukemia (CLL), pose a significant clinical challenge due to high relapse rates and dose-limit…FrontiersNiina Veitonmäki Excited to share that the co-laboration article has just

Email issues

Zermatt consulting has experience e-mail delivery issues, we apologize for the inconvenience. The issues should now be resolved and you can contact us at info@zermatt-consulting.com, niina@zermatt-consulting.com or niina@veitonmaki.com. Telephone +46-73 7207812

Happy New Year 2025

Happy New Year 2025

We are thanking all customers, and co-laboraters for the year 2024 and wishing health, happiness and new success stories for the year 2025! Lets make year 2025 successful together!

Happy holidays

Warm holiday wishes🎄 As we begin to look ahead to 2025, we wish you a joyful holiday season. May this festive period bring you happiness, success, and new exciting opportunities in the year to come.

We have soon capacity for new co-laboration opportunities

We have soon capacity for new co-laboration opportunities

We can support your drug development, discovery, in vitro and in vivo research, CRO contacts, support regulatory submission, people management, project management and more. Please contact for inquiries. info@zermatt-consulting.com or niina@veitonmaki.com

First indication of PBA-0405 activity in patient settings

First indication of PBA-0405 activity in patient settings

Pure Biologics released first biomarker data obtained in Phase O clinical study in Head and Neck patients receiving intra-tumoral injection of PBA-0405. Early results indicate that in the two out of three patient markers for tumor cell killing are increased near PBA-0405 injection sites in comparison to control injections (vehicle)

PBA-0111 received "Study may proceed" letter from FDA

PBA-0111 received "Study may proceed" letter from FDA

Pure Biologics took another significant step forward by receiving a "study may proceed" letter from the US Food and Drug Administration (FDA) to test PBA-0111 in a Phase 0 clinical study in solid tumor cancer patients. This approval marks Pure Biologics' second FDA approval shortly after the

First patient dosed with PBA-0405

First patient dosed with PBA-0405

Pure Biologics announced on July 15, 2024 the dosing of the first patient was with the candidate PBA-0405 in a Phase 0 study. The first patient, diagnosed with head and neck squamous cell carcinoma [HNSCC], was recruited at the Louisiana State University Hospital in Shreveport. Intratumoral administration of PBA-0405 will

Coming more soon

Coming more soon

This is Zermatt Consulting, a brand new site that's just getting started. Things will be up and running here shortly

PBA-0405 receives FDA "study may proceed"

PBA-0405 receives FDA "study may proceed"

We are proud to announce that Zermatt Consulting has played a significant role in Pure Biologics approval receival from the U.S. Food and Drug Administration (FDA) for an exploratory Investigational New Drug (eIND) for testing PBA-0405 in a Phase 0 clinical study in solid tumour cancer patients. About PBA-0405:

Warm holiday wishes from Zermatt Consulting!

Warm holiday wishes from Zermatt Consulting!

The year 2023 has been very busy and productive. Zermatt consulting was part of an exiting journey from drug discovery, trough research, pre-clinical and eIND application. As year 2023 is closing, we are looking forward to continuing the successful journey with our customers and co-laborators in 2024!